The Journal of Organic Chemistry
Article
1
m), 8.89 (2H, v br), 11.29 (1H, v br); H NMR (500 MHz, 50 °C,
7−8 min. The two layers were separated, and the aqueous solution was
extracted with dichloromethane. The combined organic phases were
washed with water and 5% sodium bicarbonate solution and then
evaporated under reduced pressure. The residue was purified on a
grade 3 neutral alumina column, eluting with dichloromethane, and a
dark green product fraction was collected. The solvent was removed
on a rotary evaporator, and the residue was recrystallized from
chloroform−methanol to give the porphyrinoid product (20.4 mg,
0.0292 mmol, 20%) as purple crystals, mp 288−289 °C, dec.
CDCl3) δ 1.15 (18H, s), 2.49 (6H, s), 4.05 (4H, s), 5.04 (4H, br s),
7.01−7.04 (4H, m), 7.13−7.16 (2H, m), 7.18−7.22 (4H, m), 7.27−
7.34 (10H, m), 7.96 (1H, v br), 9.16 (2H, v br); 1H NMR (500 MHz,
DMSO-d6) δ 1.02 (18H, br s), 2.33 (6H, s), 4.06 (4H, s), 5.20 (4H, s),
6.96−6.98 (4H, m), 7.07−7.11 (2H, m), 7.16−7.20 (4H, m), 7.29−
7.33 (2H, m), 7.34−7.37 (4H, m), 7.38−7.41 (4H, m), 8.34 (1H, s),
10.62 (2H, s); 13C NMR (50 °C, CDCl3) δ 14.0, 26.7, 31.9, 33.1, 65.7,
118.4, 121.7, 124.9, 125.9, 127.8, 128.1, 128.2, 128.8, 129.6, 130.5,
135.9, 137.0, 161.7; 13C NMR (500 MHz, DMSO-d6) δ 13.4, 25.9,
31.2, 32.4, 64.5, 117.3, 119.4, 124.9, 125.3, 127.0, 127.95, 127.96,
127.98, 128.3, 128.5, 128.7, 129.7, 136.0, 136.9, 160.4; HR MS (ESI)
calcd for C52H55N3O4 + H 786.4271, found 786.4272. Anal. Calcd for
C52H55N3O4: C, 79.46; H, 7.05; N, 5.35. Found: C, 79.40; H, 7.08; N,
5.47.
13,14-Diethyl-8,9,18,19-tetraphenyl-2-oxybenziporphyrin
(6c). Method A. Tetraphenyltripyrrane dibenzyl ester 1c (0.600 g,
0.703 mmol) was placed in a hydrogenation vessel and dissolved in
freshly distilled THF (150 mL), methanol (50 mL), and triethylamine
(20 drops). After flushing the solution with nitrogen, 10% palladium
on activated carbon (100 mg) was added, and the resulting mixture
was shaken under hydrogen (40 psi) at room temperature overnight.
The catalyst was removed by suction filtration, and the solvent was
removed under reduced pressure. The residue was dissolved in 5%
aqueous ammonia (50 mL), and the solution was neutralized with
acetic acid to a litmus end point while maintaining the temperature at
0−5 °C using an ice−salt bath. The resulting precipitate was suction
filtered and washed repeatedly with water to remove all traces of acid.
After drying overnight in a vacuum desiccator, tripyrrane dicarboxylic
acid 2c (0.472 g, 0.701 mmol, quantitative) was obtained as a reddish
powder. This was used for porphyrinoid synthesis without further
13,14-Diethyl-8,9,18,19-tetraphenyl-2-oxypyriporphyrin
(7c). Using method B, 3-hydroxy-2,6-pyridinedicarbaldehyde11 (22.5
mg, 0.149 mmol) was reacted with tripyrrane 2c (100 mg, 0.148
mmol). Recrystallization from chloroform−methanol gave the oxy-
pyriporphyrin (26.2 mg, 0.0375 mmol, 25%) as purple crystals, mp
>300 °C; UV−vis (1% Et3N−CHCl3) λmax (log10 ε) 432 (5.28), 451
(5.09), 546 (4.09), 587 (4.25), 610 (4.10), 670 nm (3.55); UV−vis
(1% TFA−CHCl3) λmax (log10 ε) 433 (5.21), 456 (5.11), 550 (3.95),
594 (4.29), 646 (3.91), 720 nm (3.72); 1H NMR (500 MHz, CDCl3)
δ −2.92 (1H, br s), −2.75 (1H, br s), 1.75 (6H, t, J = 7.6 Hz), 3.74
(4H, q, J = 7.6 Hz), 7.62−7.73 (12H, m), 7.83−7.88 (1H, m), 7.94−
8.00 (8H, m), 9.20 (1H, br d, J = 9.5 Hz), 9.68 (1H, s), 9.89 (1H, s),
1
9.90 (1H, s), 10.98 (1H, s); H NMR (500 MHz, TFA−CDCl3) δ
−0.50 (2H, v br), 1.55−1.59 (6H, two overlapping triplets), 3.80−3.86
(4H, two overlapping quartets), 7.60−7.66 (12H, m), 7.67−7.73 (4H,
m), 7.75−7.78 (4H, m), 8.43 (1H, d, J = 9.7 Hz), 9.54 (1H, d, J = 9.7
Hz), 9.95 (1H, s), 10.314 (1H, s), 10.316 (1H, s), 10.90 (1H, s); 13C
NMR (CDCl3) δ 18.16, 18.19, 19.8, 100.1, 100.4, 107.1, 111.6, 128.2,
128.35, 128.38, 128.90, 128.93, 132.0, 132.71, 132.74, 132.8, 133.1,
134.4, 134.5, 134.7, 145.8, 146.4, 156.7, 185.7; 13C NMR (TFA−
CDCl3) δ 17.28, 17.33, 20.1, 103.8, 104.0, 105.1, 108.5, 110.8, 113.1,
115.4, 117.6, 129.56, 129.58, 129.85, 129.88, 129.94, 131.5, 131.6,
131.7, 132.39, 132.44, 132.5, 132.6, 133.0, 135.2, 136.3, 141.5, 141.8,
142.1, 142.6, 143.0, 143.4, 143.6, 144.0, 144.1, 145.3, 145.5, 179.8;
HRMS (EI) calcd for C49H38N4O 698.3045, found 698.3031.
1
purification. H NMR (500 MHz, DMSO-d6) δ 0.62 (6H, t, J = 7.4
Hz), 1.83 (4H, q, J = 7.4 Hz), 3.77 (4H, s), 6.87−6.90 (4H, m), 7.06−
7.15 (16H, m), 9.47 (1H, br s), 10.88 (2H, v br), 11.54 (2H, br s); 13C
NMR (500 MHz, DMSO-d6) δ 16.3, 16.8, 22.4, 118.0, 118.9, 122.3,
123.2, 125.8, 126.0, 127.1, 127.3, 127.8, 128.1, 129.3, 130.4, 130.9,
132.2, 135.0, 135.3, 162.3.
12,13-Diethyl-7,8,17,18-tetraphenyl-21-carbabenzo[b]-
porphyrin (8c). Using method B, indene dialdehyde 527 (25.6 mg,
0.149 mmol) was reacted with 2c (100 mg, 0.148 mmol).
Recrystallization from chloroform−methanol gave the benzocarbapor-
phyrin (8.5 mg, 0.012 mmol, 8.0%) as purple crystals, mp >300 °C;
UV−vis (1% Et3N−CHCl3) λmax (log10 ε) 383 (4.71), 434 (5.19), 453
(sh, 4.81), 517 (4.43), 549 (sh, 3.84), 616 (3.82), 677 nm (3.88);
UV−vis (1% TFA−CHCl3) λmax (log10 ε) 315 (4.51), 408 (4.87), 447
The foregoing tripyrrane dicarboxylic acid (101.4 mg, 0.150 mmol)
was dissolved in TFA (1 mL) and stirred under nitrogen for 5 min.
The solution was diluted with dichloromethane (99 mL), 5-
formylsalicylaldehyde (22.7 mg, 0.151 mmol) was added, and the
mixture was stirred for 16 h at room temperature in the dark under a
nitrogen atmosphere. The solution was neutralized by the dropwise
addition of triethylamine, DDQ (36.5 mg) was added, and the
resulting solution stirred for an additional 1 h. The solution was
washed with water, and the solvent was removed on a rotary
evaporator. The residue was purified by column chromatography on
grade 3 neutral alumina, eluting with dichloromethane. The product
was collected as a dark green band. Recrystallization from chloro-
form−methanol gave the oxybenziporphyrin (14.4 mg, 0.021 mmol,
14%) as shiny purple crystals, mp 288−290 °C, dec; UV−vis (1%
Et3N−CHCl3) λmax (log10 ε) 438 (5.21), 465 (5.02), 545 (4.03), 586
(4.21), 639 (3.77), 709 nm (3.55); UV−vis (1% TFA−CHCl3) λmax
(log10 ε) 328 (4.56), 440 (5.21), 479 (4.95), 563 (4.01), 613 (4.10),
1
(4.97), 483 (4.73), 560 (4.19), 626 nm (4.10); H NMR (500 MHz,
CDCl3) δ −6.25 (1H, s), −3.25 (2H, v br), 1.78 (6H, t, J = 7.7 Hz),
3.81 (4H, q, J = 7.7 Hz), 7.61−7.75 (14H, m), 8.03−8.06 (8H, m),
8.62−8.66 (2H, m), 9.90 (2H, s), 10.12 (2H, s); 13C NMR (CDCl3) δ
18.4, 20.0, 98.6, 102.3, 110.3, 120.9, 126.9, 127.9, 128.0, 128.89,
128.91, 132.7, 133.0, 134.6, 135.0, 135.2, 135.37, 135.44, 135.9, 137.8,
141.4, 145.1, 154.2; HRMS (EI) calcd for C53H41N3 719.3301, found
719.3308.
12,13-Diethyl-7,8,17,18-tetraphenylazuliporphyrin (21c).
Using method B, tripyrrane 2c (100 mg, 0.148 mmol) was reacted
with 1,3-azulenedicarbaldehyde28 (27.4 mg, 0.149 mmol). The product
was purified by column chromatography on basic grade 3 alumina,
eluting initially with chloroform and then with 1−2% methanol−
chloroform. Recrystallization from chloroform−hexanes gave then
with azuliporphyrin (16.6 mg, 0.0227 mmol, 15%) as dark purple
crystals, mp >300 °C, dec; UV−vis (1% Et3N−CHCl3) λmax (log10 ε)
373 (sh, 4.83), 392 (4.83), 462 (4.71), 489 (4.86), 668 nm (4.09);
UV−vis (1% TFA−CHCl3) λmax (log10 ε) 380 (4.92), 478 (5.00), 646
1
634 nm (4.14); H NMR (500 MHz, CDCl3) δ −5.86 (1H, br d, J =
2.0 Hz), 1.70 (6H, t, J = 7.6 Hz), 3.63−3.68 (4H, two overlapping
quartets), 7.37 (1H, d, J = 9.4 Hz), 7.59−7.70 (12H, m), 7.87−7.94
(8H, m), 8.66 (1H, dd, J = 2.2, 9.6 Hz), 9.45 (1H, s), 9.51 (1H, s),
9.59 (1H, s), 10.55 (1H, s); 13C NMR (CDCl3) δ 17.97, 18.05, 19.8,
96.8, 98.6, 110.0, 113.4, 115.5, 123.4, 127.6, 128.07, 128.14, 128.40,
128.45, 128.90, 128.92, 128.94, 130.8, 132.0, 132.49, 132.51, 132.8,
132.9, 134.0, 134.27, 134.33, 134.35, 134.6, 135.5, 136.3, 138.2, 140.0,
141.1, 143.1, 145.4, 145.9, 147.8, 155.8, 157.3, 188.1; HRMS (EI)
calcd for C50H39N3O 697.3093, found 697.3097. Anal. Calcd for
C50H39N3O·0.3CHCl3: C, 82.34; H, 5.39; N, 5.73. Found: C, 82.50; H,
4.99; N, 5.93.
1
nm (4.26); H NMR (500 MHz, CDCl3) δ 1.57 (6H, t, J = 7.6 Hz),
2.65 (1H, br s), 2.79 (1H, s), 3.39 (4H, q, J = 7.6 Hz), 7.44−7.48 (2H,
m), 7.50−7.61 (10H, m), 7.65 (2H, t, J = 9.5 Hz), 7.71−7.75 (5H, m),
7.77−7.80 (4H, m), 8.35 (2H, s), 9.16 (2H, s), 9.19 (2H, d, J = 9.6
Hz); 1H NMR (500 MHz, TFA−CDCl3) δ −2.65 (1H, s), −1.32 (2H,
v br), 1.63 (6H, t, J = 7.7 Hz), 3.72 (4H, q, J = 7.7 Hz), 7.66−7.75
(12H, m), 7.78−7.81 (4H, m), 7.85−7.88 (4H, m), 8.53 (1H, t, J = 9.5
Hz), 8.61 (2H, t, J = 9.5 Hz), 9.60 (2H, s), 9.86 (2H, d, J = 9.6 Hz),
10.39 (2H, s); 13C NMR (CDCl3) δ 16.8, 18.8, 95.7, 112.6, 126.8,
127.0, 128.2, 128.3, 131.5, 131.7, 133.2, 135.6, 135.88, 135.91, 136.3,
Method B. Tripyrrane 2c (100 mg) and 5-formylsalicylaldehyde
(22.4 mg, 0.149 mmol) were stirred with TFA (5 mL) for 1 h at room
temperature under nitrogen. The solution was diluted with dichloro-
methane and shaken with a 0.1% aqueous ferric chloride solution for
9781
dx.doi.org/10.1021/jo301945f | J. Org. Chem. 2012, 77, 9774−9783